[GlobeNewswire] - TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at the 49th Annual Meeting of the American ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment